

## Special Issue

# NK Cells in the Tumor Microenvironment: Immunosuppressive Mechanisms and Therapy

### Message from the Guest Editors

Natural killer (NK) cells represent the innate counterparts of cytotoxic T lymphocytes, poised to rapidly engage in cell-mediated cytotoxicity and the release of potent proinflammatory cytokines. Their functions are largely regulated through surface-activating and inhibitory receptors which probe their tissue microenvironment for signs of infection or malignancy. Therapeutic manipulation of these opposing receptors holds great promise for clinical intervention. In this Special Issue, we explore the mechanisms malignant cells employ to inhibit NK cell surveillance, as well as therapeutic strategies to overcome these immunosuppressive pathways and enhance NK cell activity.

### Guest Editors

Dr. Alexander Barrow

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia

Dr. Julian Vivian

1. St. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia  
2. Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia

### Deadline for manuscript submissions

5 December 2025



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/196123](https://mdpi.com/si/196123)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)